The role of P21/Cdc42/Rac1-activated kinases (PAK) in prostate cancer.

P21/Cdc42/Rac1 激活激酶 (PAK) 在前列腺癌中的作用。

• 批准号: MR/J010855/1
• 负责人: Karan Wadhwa
• 金额: $ 23.62万
• 依托单位: University of Cambridge
• 依托单位国家: 英国
• 项目类别: Fellowship
• 财政年份: 2012
• 资助国家: 英国
• 起止时间: 2012 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FJ010855%2F1
• 关键词: role; P21; Cdc42; Rac1; activated

Prostate cancer is the second leading cause of cancer death in men in the West. It is initially treatable with androgen deprivation therapy but eventually progresses to become insensitive to the treatment we have. The next stage is to have chemotherapy, which gives an average survival of between 10 and 20 months. We know that the main receptor responsible for prostate cancer growth (androgen receptor) has an effect on the different cell signaling pathways within the cell, particularly those involved in cell growth and cell movement. New links have shown one of the ways this relationship occurs is through energy regulating pathways. What we are aiming to do is to show a link between the energy regulating pathways and cell growth and cell movement. The aim is to concentrate on one of these mechanisms - the Rac1/PAK1 pathway - and determine its role in prostate cancer growth and metastasis. We know that more aggressive prostate cancers have higher levels of Rac1 and PAK1 but we do not yet know what their role is in the development of prostate cancer or its effect on cancer growth and spread. We aim to find out the mechanisms by which it works and the pathways that regulate it. This will initially be in the laboratory in cells but also on human tissue from specimens. The aim is to eventually discover new targets for the development of new medicines to help control prostate cancer.

前列腺癌是西方男性癌症死亡的第二大原因。它最初可以用雄激素剥夺疗法治疗，但最终进展到对我们的治疗不敏感。下一阶段是化疗，平均生存期在10到20个月之间。我们知道，负责前列腺癌生长的主要受体（雄激素受体）对细胞内不同的细胞信号传导途径有影响，特别是那些参与细胞生长和细胞运动的细胞信号传导途径。新的联系表明，这种关系发生的方式之一是通过能量调节途径。我们的目标是展示能量调节途径与细胞生长和细胞运动之间的联系。目的是集中在这些机制之一-Rac 1/PAK 1通路-并确定其在前列腺癌生长和转移中的作用。我们知道更具侵袭性的前列腺癌具有更高水平的Rac 1和PAK 1，但我们还不知道它们在前列腺癌发展中的作用或其对癌症生长和扩散的影响。我们的目标是找出它的工作机制和调节它的途径。这将首先在实验室中的细胞，但也对人体组织标本。其目的是最终发现新的靶点，用于开发新的药物来帮助控制前列腺癌。